Furthermore, Gal-9 also seems to have a better therapeutic window in stem cells than CQ, as CB-derived healthy CD34+ stem cells were equally sensitive to treatment with CQ as AML stem cells [36], whereas Gal-9 did not have any negative impact on CB-derived healthy CD34+ stem cells in the current study. This evidence concerns the gene CD34 and acute myeloid leukemia.